Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Phase 2

Completed

• Conditions: Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer
• Interventions: Drug: PCI-27483; Drug: Gemcitabine

• Registration Number: NCT01020006
• Lead Sponsor: Pharmacyclics LLC.

Brief Summary

The purpose of this study is to evaluate the safety and tolerability of selected dose 1.2mg/kg BID dosage administered subcutaneously (SC) administered PCI-27483 to metastatic or locally advanced pancreatic cancer patients receiving concurrent therapy with intravenously administered gemcitabine for 12 weeks.

Detailed Description

This study will be conducted in three segments: Part A, Part B and Part C. Parts A and B are 12 weeks of treatment followed by 4 weeks of evaluation. In part A patients will dose-escalate up to three dose levels of PCI-27483 administered as subcutaneous (SC) injections twice-daily (BID). Part B to start once 4th patient completes 90 of 112 doses in 8 weeks. In part B patients are randomized to PCI-27483 and gemcitabine (active arm) OR gemcitabine only (control arm). PCI-27483 doses in both Part A and B will be administered in combination with a standard regimen of gemcitabine. Patients with a tumor response or stable disease at 12 weeks will have the opportunity to continue PCI-27483 treatment until disease progression or the Investigator considers the study treatment to be no longer tolerable. Treatment with gemcitabine in either the active or control arm may continue until a standard course of gemcitabine therapy has been completed. Patients will complete Part A or Part B after 16 weeks on study regardless of treatment duration. Evaluable patients will roll over into part C and be followed for 12 months from enrollment (first dose).

Study Timeline

• Study Start: 2009-11
• Study First Submitted: 2009-11-20
• Study First Submitted QC: 2009-11-23
• Study First Posted: 2009-11-25
• Primary Completion: 2012-08
• Results First Submitted: 2014-02-18
• Results First Submitted QC: 2014-02-18
• Status Verified: 2014-04
• Results First Posted: 2014-04-02
• Last Update Submitted: 2014-04-04
• Last Update Posted: 2014-04-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

1. Men or women at least 18 years old

2. Body weight ≥ 40 and ≤ 100 kg.

3. Part A: Metastatic ductal adenocarcinoma of the pancreas diagnosed ≤ 4 months prior to enrollment. (Locally advanced does not have any criteria)

4. Part B: Locally advanced ductal adenocarcinoma of the pancreas diagnosed ≤ 3 months prior to enrollment or metastatic ductal adenocarcinoma diagnosed ≤ 2 months.

5. Measurable disease by spiral CT scan (SCT) in accordance with RECIST criteria.

6. Patients after non-curative surgery are eligible if at least 4 weeks after surgery and recovered from significant surgical morbidity.

7. Estimated life expectancy of at least 4 months.

8. ECOG performance status 0 to 1.

9. Normal baseline coagulation function as defined by:

   1. PT 10-16 seconds, and
   2. aPTT 22-38 seconds.

10. Agree to not participate in contact sports or strenuous activity while taking PCI-27483.

11. Ability to understand the study, willingness to participate in the study for the study duration, and ability to provide written informed consent to participate.

Exclusion Criteria

1. History of any clinically significant medical condition that, in the opinion of the Principal Investigator, would interfere with the study evaluation or interpretation.

2. Known history of brain metastases.

3. Any evidence of intra-cranial hemorrhage based on head CT scan within 30 days of enrollment.

4. History of disease progression while being treated with gemcitabine.

5. Radiotherapy of the primary tumor or unwillingness to defer radiotherapy of the primary tumor until > 3 months from initiation of treatment.

6. History of venous thromboembolism (eg, deep vein thrombosis, pulmonary embolism,and arterial thromboembolism) or other indications for anticoagulant treatment (eg,mechanical heart values, atrial fibrillation, etc.) within the last year. Local thrombus in the mesenteric or portal vein is acceptable.

7. Uncontrolled hypertension (systolic > 160 or diastolic > 100 mm Hg on medical treatment).

8. Continued anticoagulation therapy or anticoagulation therapy within 2 months prior to enrollment, except for perisurgical prophylaxis which must have ceased 2 weeks before enrollment.

9. Contraindication to systemic anticoagulation.

10. Continued treatment with antiplatelet drugs including aspirin, clopidogrel, etc. within the past 72 hours.

11. Known history of clinically significant or recurrent bleeding episodes, including significant bleeding after surgery, childbirth, or dental extraction.

12. Patients with documented invasion of adjacent organs by CT scan (e.g. stomach, duodenum) are not eligible

13. Patients known to have esophageal varicose are not eligible

14. Known history of a congenital coagulation factor deficiency.

15. Known acquired or hereditary platelet disorder.

16. Known history of immunodeficiency.

17. Women of child-bearing potential or sexually active men, unwilling to use adequate contraceptive protection during the course of the study.

18. Pregnant or lactating women (female patients of childbearing potential must have a negative serum pregnancy test within 14 days of first day of drug dosing, or if positive, pregnancy ruled out by ultrasound).

19. Laboratory Abnormalities:

    1. Serum creatinine > 2 mg/dL or creatinine clearance < 50 mL/minute (using Cockroft Gault formula)
    2. AST and ALT ≥ 4.0 x upper limit of normal (ULN).
    3. Bilirubin ≥ 3 mg/dL.
    4. Alkaline phosphatase > 5 x ULN.
    5. Albumin < 2.0g/dL.
    6. Hemoglobin < 9.0 g/dL.
    7. Platelet count < 100,000/μL.

20. Evidence of active gastrointestinal tract bleeding, including guaiac stool positivity,excluding hemorrhoidal bleeding

21. Chronic active hepatitis B or C.

22. Known HIV infection.

23. Participation in any study of an investigational device, medication, biologic, or other agent within 30 days prior to enrollment, or planned participation within the study duration.

24. Risk factors for, or use of medications known to prolong QTc interval or that may be associate with Torsades de Pointes within 7 days of treatment start (see Appendix J. Risk Factors for Drug-induced Torsades de Pointes).

25. QTc prolongation (defined as a QTc ≥ 450 msec) or other significant ECG abnormalities including 2nd degree AV block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min). If 2 screening ECGs have a QTc ≥ 450 msec, the ECGs can be submitted for a centralized, cardiologic evaluation and if determined to be < 450 msec then the patient is eligible.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
PCI-27483 + Gemcitabine	Gemcitabine	Part A: Subjects received PCI-27483 0.8 mg/kg BID as initial dose and may be escalated to 1.2, and 1.5 mg/kg BID. At the same time, subjects received Gemcitabine 1000 mg/m2 weekly intravenous infusion. Part B: Subjects received the PCI-27483 at 1.2 mg/kg BID and Gemcitabine 1000 mg/m2 weekly intravenous infusion.
Gemcitabine	Gemcitabine	Subjects receive Gemcitabine 1000 mg/m2 weekly intravenous infusion.
PCI-27483 + Gemcitabine	PCI-27483	Part A: Subjects received PCI-27483 0.8 mg/kg BID as initial dose and may be escalated to 1.2, and 1.5 mg/kg BID. At the same time, subjects received Gemcitabine 1000 mg/m2 weekly intravenous infusion. Part B: Subjects received the PCI-27483 at 1.2 mg/kg BID and Gemcitabine 1000 mg/m2 weekly intravenous infusion.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Treatment Emergent Adverse Events (AEs)	First dose until 28 days after last dose of PCI-27483 or gemcitabine whichever occurs last in the assigned part (A or B).	Clinically meaningful toxicity adverse events will be defined in accordance with by CTCAE v3.0

Trial Locations

Locations (17)

Park Nicollet Institute; 🇺🇸 St. Louis Park, Minnesota, United States

Space Coast Medical Associates; 🇺🇸 Titusville, Florida, United States

Columbia University; 🇺🇸 New York, New York, United States

Gettysburg Cancer Center; 🇺🇸 Gettysburg, Pennsylvania, United States

Pacific Cancer Medical Center; 🇺🇸 Anaheim, California, United States

Investigative Clinical Research of Indiana; 🇺🇸 Indianapolis, Indiana, United States

Summa Health System; 🇺🇸 Akron, Ohio, United States

Gabrail Cancer Center Research; 🇺🇸 Canton, Ohio, United States

Associates in Oncology and Hematology; 🇺🇸 Chattanooga, Tennessee, United States

University of Vermont/Vermont Cancer Center; 🇺🇸 Burlington, Vermont, United States

Beth Israel Cancer Center; 🇺🇸 New York, New York, United States

Kenthucky Cancer Clinic; 🇺🇸 Hazard, Kentucky, United States

Sammons Cancer Center; 🇺🇸 Dallas, Texas, United States

University of Rochester; 🇺🇸 Rochester, New York, United States

Charleston Hematology Oncology Associates; 🇺🇸 Charleston, South Carolina, United States

South Carolina Cancer Specialists, PA; 🇺🇸 Hilton Head, South Carolina, United States

TGen Clinical Reserch Services at Scottsdale Healthcare; 🇺🇸 Scottsdale, Arizona, United States